CoChat
Sign Up
Cited by 110

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer

Cappello, Paola, Rolla, Simona, Chiarle, Roberto, Principe, Moitza, Cavallo, Federica, Perconti, Giovanni, Feo, Salvatore, Giovarelli, Mirella, Novelli, Francesco·2013·Gastroenterology
DOI 10.1053/j.gastro.2013.01.020
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2013.01.020

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. Jemal, 2008, Cancer statistics, 2008, CA Cancer J Clin, 58, 71
  2. Omura, 2009, Epigenetics and epigenetic alterations in pancreatic cancer, Int J Clin Exp Pathol, 2, 310
  3. Tomaino, 2007, Autoantibody signature in human ductal pancreatic adenocarcinoma, J Proteome Res, 6, 4025, 10.1021/pr070281a · DOI
  4. Tomaino, 2011, Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer, J Proteome Res, 10, 105, 10.1021/pr100213b · DOI
  5. Cappello, 2009, An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen, Int J Cancer, 125, 639, 10.1002/ijc.24355 · DOI
  6. Capello, 2011, α-enolase: a promising therapeutic and diagnostic tumor target, FEBS J, 278, 1064, 10.1111/j.1742-4658.2011.08025.x · DOI
  7. Pancholi, 2001, Multifunctional alpha-enolase: its role in diseases, Cell Mol Life Sci, 58, 902, 10.1007/PL00000910 · DOI
  8. Hingorani, 2003, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer Cell, 4, 437, 10.1016/S1535-6108(03)00309-X · DOI · Paper page
  9. Hruban, 2006, Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations, Cancer Res, 66, 95, 10.1158/0008-5472.CAN-05-2168 · DOI
  10. Giallongo, 1986, Molecular cloning and nucleotide sequence of a full-length cDNA for human alpha enolase, Proc Natl Acad Sci U S A, 83, 6741, 10.1073/pnas.83.18.6741 · DOI
  11. Giovarelli, 2000, Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes, J Immunol, 164, 3200, 10.4049/jimmunol.164.6.3200 · DOI
  12. Clark, 2007, Dynamics of the immune reaction to pancreatic cancer from inception to invasion, Cancer Res, 67, 9518, 10.1158/0008-5472.CAN-07-0175 · DOI · Paper page
  13. Martinez, 2008, Regulation and function of proinflammatory TH17 cells, Ann N Y Acad Sci, 1143, 188, 10.1196/annals.1443.021 · DOI
  14. Kryczek, 2009, Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments, Blood, 114, 1141, 10.1182/blood-2009-03-208249 · DOI
  15. Laheru, 2005, Immunotherapy for pancreatic cancer—science driving clinical progress, Nat Rev Cancer, 5, 459, 10.1038/nrc1630 · DOI
  16. Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
  17. Weiner, 2012, Antibody-based immunotherapy of cancer, Cell, 148, 1081, 10.1016/j.cell.2012.02.034 · DOI
  18. Shuptrine, 2012, Monoclonal antibodies for the treatment of cancer, Semin Cancer Biol, 22, 3, 10.1016/j.semcancer.2011.12.009 · DOI
  19. Hasbold, 1999, Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a, J Immunol, 163, 4175, 10.4049/jimmunol.163.8.4175 · DOI
  20. Guo, 2011, Targeting intracellular oncoproteins with antibody therapy or vaccination, Sci Transl Med, 3, 10.1126/scitranslmed.3002296 · DOI
  21. Lopez-Alemany, 2003, Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-enolase, Am J Hematol, 72, 234, 10.1002/ajh.10299 · DOI
  22. Wygrecka, 2009, Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung, Blood, 113, 5588, 10.1182/blood-2008-08-170837 · DOI
  23. Gnerlich, 2010, Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer, J Immunol, 185, 4063, 10.4049/jimmunol.0902609 · DOI
  24. Fujita, 2008, Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation, Prostate, 68, 872, 10.1002/pros.20755 · DOI
  25. DuPage, 2011, Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression, Cancer Cell, 19, 72, 10.1016/j.ccr.2010.11.011 · DOI
  26. Weber, 1998, Tumor immunity and autoimmunity induced by immunization with homologous DNA, J Clin Invest, 102, 1258, 10.1172/JCI4004 · DOI
  27. Bowne, 1999, Coupling and uncoupling of tumor immunity and autoimmunity, J Exp Med, 190, 1717, 10.1084/jem.190.11.1717 · DOI
  28. Overwijk, 1998, gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand, J Exp Med, 188, 277, 10.1084/jem.188.2.277 · DOI
  29. Li, 2010, Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going?, JOP, 11, 310
  30. Kryczek, 2009, Endogenous IL-17 contributes to reduced tumor growth and metastasis, Blood, 114, 357, 10.1182/blood-2008-09-177360 · DOI
  31. Martin-Orozco, 2009, T helper 17 cells promote cytotoxic T cell activation in tumor immunity, Immunity, 31, 787, 10.1016/j.immuni.2009.09.014 · DOI
  32. Zou, 2010, T(H)17 cells in tumour immunity and immunotherapy, Nat Rev Immunol, 10, 248, 10.1038/nri2742 · DOI
  33. Kroemer, 2007, Death, danger, and immunity: an infernal trio, Immunol Rev, 220, 5, 10.1111/j.1600-065X.2007.00576.x · DOI
  34. Suzuki, 2005, Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, Clin Cancer Res, 11, 6713, 10.1158/1078-0432.CCR-05-0883 · DOI · Paper page
  35. Ko, 2007, A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model, Cancer Res, 67, 7477, 10.1158/0008-5472.CAN-06-4639 · DOI
  36. Diaz-Montero, 2009, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy, Cancer Immunol Immunother, 58, 49, 10.1007/s00262-008-0523-4 · DOI
  37. Sistigu, 2011, Immunomodulatory effects of cyclophosphamide and implementations for vaccine design, Semin Immunopathol, 33, 369, 10.1007/s00281-011-0245-0 · DOI
  38. Kraman, 2010, Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha, Science, 330, 827, 10.1126/science.1195300 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Cappello, P., Rolla, S., Chiarle, R., Principe, M., Cavallo, F., Perconti, G., Feo, S., Giovarelli, M., & Novelli, F.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2013-05
Volume
144
Issue
5
Pages
1098-1106
ISSN
0016-5085
DOI
10.1053/j.gastro.2013.01.020
Cited by
110
References
3
Language
en
Licence
Funders
  • Association for International Cancer Research
  • Associazione Italiana per la Ricerca sul Cancro (11643, 12182)
  • Seventh Framework Programme (256974)
  • Fondazione Italiana per la Ricerca sul Cancro
  • Regione Piemonte
  • European Commission
  • Ministero dell’Istruzione, dell’Università e della Ricerca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review